[An immunoregulator of asthma: Ribomunyl].
A double blind check was conducted in two groups of patients with asthma to test ribosomal fraction (Ribomunyl) in a new tablet form: -the first group of 15 patients received the active medicine; -the second group of 9 patients were given placebos. The therapy consisted in prescribing 3 tablets a day for the first 4 days of the week for 3 weeks, next to stop treatment for one month, then to resume treatment for 4 days every month. Clinical improvement was reported in patients who were given the medicine. The "Rosettes" Test is in favor of a stimulation of T lymphocytes with correction of the cellular mediation deficit in the groups that received treatment.